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Abstract
Background: Recent data in esophageal cancer suggests the variant allele of a single-nucleotide polymorphism
(SNP) in XRCC1 may be associated with resistance to radiochemotherapy. However, this SNP has not been assessed
in a histologically homogeneous clinical trial cohort that has been treated with a uniform approach. In addition,
whether germline DNA may serve as a surrogate for tumor genotype at this locus is unknown in this disease. Our
objective was to assess this SNP in relation to the pathologic complete response (pCR) rate in subjects with
esophageal adenocarcinoma who received cisplatin-based preoperative radiochemotherapy in a multicenter clinical
trial (Eastern Cooperative Oncology Group 1201). As a secondary aim, we investigated the rate of allelic imbalance
between germline and tumor DNA.
Methods: Eighty-one eligible treatment-naïve subjects with newly diagnosed resectable esophageal
adenocarcinoma received radiotherapy (45 Gy) concurrent with cisplatin-based chemotherapy, with planned
subsequent surgical resection. The primary endpoint was pCR, defined as complete absence of tumor in the
surgical specimen after radiochemotherapy. Using germline DNA from 60 subjects, we examined the base-excision
repair SNP, XRCC1 Arg399Gln, and 4 other SNPs in nucleotide excision (XPD Lys751Gln and Asp312Asn, ERCC1 3’
flank) and double-stranded break (XRCC2 5’ flank) repair pathways, and correlated genotype with pCR rate. Paired
tumor tissue was used to estimate the frequency of allelic imbalance at the XRCC1 SNP.
Results: The variant allele of the XRCC1 SNP (399Gln) was detected in 52% of subjects. Only 6% of subjects with
the variant allele experienced a pCR, compared to 28% of subjects without the variant allele (odds ratio 5.37 for
failing to achieve pCR, p = 0.062). Allelic imbalance at this locus was found in only 10% of informative subjects,
suggesting that germline genotype may reflect tumor genotype at this locus. No significant association with pCR
was noted for other SNPs.
Conclusions: Assessed for the first time in a prospective, interventional trial cohort of esophageal adenocarcinoma,
XRCC1 399Gln was associated with resistance to radiochemotherapy. Further investigation of this genetic variation
is warranted in larger cohorts. In addition, these data indicate that germline genotype may serve as a surrogate for
tumor genotype at this locus.
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Background
Esophageal adenocarcinoma (EAC) is one of the fastest
rising cancers in the West, particularly among white
men[1]. Survival remains poor despite experimentation
with numerous cytotoxic agents and therapeutic
approaches, as well as improvements in diagnostic, sur-
gical, and radiation technique[2]. In the U.S., a widely
used standard to attempt to cure locally advanced dis-
ease, which is a common stage at presentation, is to
provide concurrent radiochemotherapy (RCT) followed
by surgery. Cisplatin often forms the base of the che-
motherapy regimen[3].
This approach causes considerable toxicity in the vast
majority of patients. Moreover, therapies are given with
little foreknowledge of outcome. Therefore, one method
to improve outcomes in EAC is to identify which
patients will respond best to a particular therapeutic
approach or agent - or, conversely, to identify patients
who will most likely fail standard therapy so as to deli-
ver alternative therapy at or near the outset[4]. Such
patient stratification holds the potential for maximizing
efficacy and minimizing toxicity.
Current methods of patient stratification in the tri-
modality setting - e.g., tumor grade, lymph node status,
and other clinicopathologic traits - inadequately forecast
clinical outcome. Therefore, the identification of biologic
or molecular predictors is a rational step to tailor ther-
apy according to an individual clinical-molecular profile.
Importantly, EAC represents a useful human model in
which to study radiochemoresistance in gastrointestinal
carcinomas. RCT leads to complete obliteration of
tumor (i.e., complete pathologic response [pCR]) in
approximately 25% of EAC patients [5]. pCR has been
repeatedly shown to be one of the strongest prognosti-
cators of long-term outcome in EAC, associated with a
2- to 4-fold longer median overall survival[6-8]. Its
importance is underscored by its increasing use as a pri-
mary endpoint in clinical trials for esophageal cancer.
RCT typically leads to a higher pCR rate in EAC than in
other gastrointestinal carcinomas, including those of the
rectum[9] or pancreas[10].
Recent attention has focused on genetic variations in
DNA repair pathways as a strategy for predicting
response to DNA-damaging agents. DNA lesions
induced by radiotherapy or cisplatin are repaired by the
base excision (BER) and double-stranded break repair
(DSBR) or by the nucleotide excision repair (NER) path-
ways, respectively. Key enzymes in these multistep com-
plexes are XRCC1 (BER), XRCC2 (DSBR), and ERCC1
and XPD (both NER)[11]. It has been hypothesized that
impaired BER/DSBR/NER activity in tumor cells leads
to greater DNA damage after treatment with platins
and/or ionizing radiation, thus causing greater tumor
cell death[12-14]. Alternatively, greater DNA damage
and genetic instability may produce tumor heterogene-
ity, giving rise to malignant clones that resist apoptosis
after platin or radiation exposure[15].
Single nucleotide polymorphisms (SNP) in these path-
ways may alter DNA repair capacity. SNPs in the
XRCC1 gene (Arg399Gln) and XPD gene (Lys751Gln)
have been associated with increased DNA damage
[16,17]. Studies of these SNPs in EAC are only recently
emerging. Efforts to identify markers that predict radio-
resistance, which encompasses the radiosensitizing
effects of chemotherapy, would focus naturally on BER
or DSBR genes. A co-investigator (X.W.) found that the
XRCC1 Arg399Gln SNP (BER) was associated with pCR
in esophageal cancer patients treated with cisplatin-
based RCT and surgery[18]. However, this cohort was
retrospectively collected over a long period (1985-2003),
received heterogeneous therapeutic approaches (e.g.,
induction chemo prior to combined RCT were
included), and combined squamous cell carcinoma
(ESCC) and adenocarcinoma (EAC) histology. ESCC and
EAC appear to be distinct from one another in epide-
miology and biology[1,2,19]. Our objective in the cur-
rent study was to build on this recent finding, by
assessing this SNP and 4 others (ERCC1, XPD, XRCC2)
in a cohort of only-EAC subjects, enrolled to a prospec-
tive, interventional clinical trial during a recent and
short period and treated with cisplatin-based RCT in
the first-line setting, without induction chemotherapy.
We found that the relationship between the XRCC1
SNP and pCR pointed in the same direction as found by
our co-investigator. To our knowledge, this is the first
assessment of this SNP in EAC patients receiving RCT
in a prospective clinical trial.
In addition, we assessed whether germline genotype
may serve as a surrogate for tumor genotype at this
XRCC1 SNP by examining allelic imbalance (AI). AI is
the loss or gain of a DNA region in tumor (as compared
to germline) cells. This issue has relevance in both the
research and clinical context. Studies evaluating the rela-
tion between SNPs and therapeutic efficacy in humans
have typically studied germline DNA (peripheral blood
lymphocytes or normal tissue) under the assumption
that germline genotype usually reflects tumor genotype
(i.e., that AI is rare at these loci). However, the rate of
AI in resectable EAC at this XRCC1 SNP is unknown. A
low rate of AI would provide biologic plausibility that
germline genotype may be used as a surrogate for
tumor genotype at these loci in predicting treatment
response. Therefore, we examined tumor tissues with
matched histologically normal tissues to assess AI. We
found that AI at this XRCC1 SNP is uncommon; this
finding supports the use of germline DNA, which is far
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more accessible clinically, when attempting to use this
SNP to predict therapeutic tumor response in the tumor
using this SNP to therapy.
Methods
Subjects, endpoints
DNA was obtained from subjects enrolled in ECOG trial
E1201. Briefly, E1201 was a multicenter, randomized
phase II trial (2002-04) that enrolled treatment-naïve
subjects with newly diagnosed adenocarcinoma of eso-
phagus or gastroesophageal junction (tumor extension
≤2 cm into gastric cardia)[20]. Other eligibility criteria
included: locally advanced stage (i.e., T2-3N0M0, T1-3
N1M0 or T1-3N0-1M1a), surgically resectable disease (T1-3
but not T4), ECOG performance status 0-1, and staging by
endoscopic ultrasound with esophagogastroduodenoscopy
and CT of the chest and abdomen. Subjects in both arms
received radiotherapy to 45 Gy administered at 1.8 Gy per
day, 5 days per week for 5 weeks, concurrently with che-
motherapy. One arm received cisplatin 30 mg/m2 days 1,
8, 22, 29, and irinotecan 65 mg/m2 days 1, 8, 22, 29. The
other arm received cisplatin 30 mg/m2 days 1, 8, 15, 22,
29, and paclitaxel 50 mg/m2 (1 hr) days 1, 8, 15, 22, 29.
Subjects in both arms underwent surgical resection
approximately 5 weeks after the completion of RCT. The
primary endpoint of E1201 as well as the current study
was pCR - i.e., the complete absence of tumor in the
resected specimen subsequent to RCT; pCR was assessed
by local geographic sites during E1201, not by central
review. Secondary endpoints were progression-free survi-
val (PFS) and overall survival (OS).
Retrieval and processing of specimens
Stored paraffin-embedded tissue specimens were
obtained from the ECOG Pathology Coordinating
Office. Both pretreatment biopsies and posttreatment
resection samples were obtained for each subject when-
ever available. Fresh hematoxylin and eosin-stained sec-
tions (H&Es) were generated, then marked by an
esophageal anatomic pathologist (E.A.M.) for areas con-
taining only histologically non-malignant tissue or areas
enriched (>60%) in tumor cells. Areas of Barrett’s meta-
plasia and dysplasia were avoided. These H&Es were
used as references for macrodissection of unstained
slides. DNA was extracted from macrodissected speci-
mens using the Qiagen QIAamp DNA FFPE Tissue Kit
(Valencia, CA) following manufacturer’s instructions
Genotyping
The Arg399Gln SNP within the X-ray repair comple-
menting defective repair in Chinese hamster cells 1
(XRCC1) gene was chosen based on its prior association
with complete pathologic response in esophageal cancer
patients treated with RCT[18]. Other SNPs were
selected if: (1) residing in a NER, BER, or DSBR pathway
gene; and (2) previously associated with clinical outcome
in solid-tumor patients treated with platinum-based che-
motherapy[12,21-23] or with cancer risk[24]. Four addi-
tional SNPs were identified in 3 genes: excision repair
cross-complementing rodent repair deficiency, comple-
mentation group 2 (XPD/ERCC2, Lys751Gln and
Asp312Asn); excision repair cross-complementing
rodent repair deficiency, complementation group 1
(ERCC1 3’ flank, also known as “C8092A”); X-ray repair
complementing defective repair in Chinese hamster cells
2 (XRCC2 5’ flank, also known as “-7985T > C”). PCR
and extension primers were designed on the Sequenom
Assay Designer 3.1 Software (San Diego, CA) based on
sequences available through the National Center for
Biotechnology Information (dbSNP; http://www.ncbi.
nlm.nih.gov/projects/SNP)). Allelotyping was performed
using mass spectrometry-based allelotyping software and
matrix-assisted laser desorption ionization-time of flight
spectrometry (MALDITOF; MassArray System, Seque-
nom, San Diego, CA) following the manufacturer’s
instructions[25]. All samples were run in triplicate. The
analysis of the spectra was done using the Sequenom
Allelotyping Software Typer Version 4.0 (San Diego,
CA; http://www.sequenom.com). MALDITOF was used
to determine allelic imbalance at the XRCC1 Arg399Gln
loci by dividing the allele frequency ratio of the tumor
sample by the allele frequency ratio of the correspond-
ing normal sample[26,27]. A sample was scored as
showing allelic imbalance if this quotient was ≤0.6 or
≥1.67 (indicating that one of the alleles had decreased
40% or more)[26,27].
Analytic and statistical approach
Data was pooled across both arms of the parent study
and analyzed at ECOG. Lab investigators remained
blinded to individual subject data throughout the study,
including during data analysis. Genotypes were dichoto-
mized a priori into 2 groups: (1) major homozygote or
(2) variant allele group (heterozygote or variant-allele
homozygote)[18]. Univariate comparisons were made
between each SNP and clinical endpoint. Multivariate
adjustments were not performed because covariates (e.g.,
age, performance status) were not associated with any
endpoint in univariate analyses. Exact logistic regression
was used to estimate odds ratios (OR) and 95% confi-
dence intervals (CI). All p-values and CIs are two-sided.
Analyses were done in SAS version 8.2 (Cary, NC) for
UNIX (SunOS). Using R2 correlation (Haploview soft-
ware 4.2, broadinstitute.org), linkage was assessed
among the four SNPs on 19q (XPD, ERCC1, XRCC1).
R2 ≥0.80 were considered significant. Hardy Weinberg
equilibrium analysis for each SNP was calculated using
R statistical software (http://www.r-project.org).
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The study was approved by the ECOG Laboratory
Science Committee, ECOG Gastrointestinal Committee,
and the Institutional Review Boards of Johns Hopkins
and Mayo Clinic. All subjects provided informed consent.
Results
Assembly and description of cohort
Of 81 eligible subjects in E1201, 60 (74%) consented to
correlative lab studies and had sufficient DNA. These 60
subjects form the primary study population of the current
analysis (Figure 1). Baseline clinicopathologic traits were:
median age 57 years (38-76); male 88%; white 93%, black
2%, Hispanic 2%, Asian 3%; node-negative (T2-3N0M0)
28%, node-positive (T1-3 N1M0 or T1-3N0-1M1a) 72%;
ECOG performance status 0 (65%) and 1 (35%); mid- (2%)
and lower thoracic (45%) esophagus, gastroesophageal
junction (48%), esophagus not otherwise specified (3%),
and unknown (2%). Ten subjects achieved a pCR. The
clinicopathologic features of the current study population
are similar to those of the parent E1201 cohort (data not
shown). Median PFS and OS were 46.5 and 46.7 months,
respectively.
Germline genotype and outcome
All subjects were successfully genotyped for all evaluated
SNPs. The variant allele of the XRCC1 SNP (399Gln)
was detected in 52% of subjects. As shown in Table 1,
only 6% of subjects with the variant allele experienced a
pCR, compared to 28% of subjects without the variant
allele (OR 5.37 for failing to achieve pCR [95% CI 0.94,
57.0], p = 0.062). No significant association with pCR
was noted for other SNPs, and no SNP was associated
with PFS or OS (Table 2). Paired tumor tissue was avail-
able in 21 of 22 informative (germline heterozygote)
subjects. AI was present in 2 (10%) of 21 informative
subjects. No significant linkage was noted for the SNPs
genotyped on 19q.
Hardy-Weinberg analysis was performed in 68 sub-
jects total, consisting of the 60 patients from the current
study cohort and 8 additional subjects who enrolled in
E1201 but were later deemed ineligible for the parent
study. All SNPs were in Hardy-Weinberg equilibrium
(p > 0.15) except XRCC1 Arg399Gln (p = 0.028). For
XRCC1, the expected vs observed genotype frequencies
(i.e., number of subjects) were 28.5 vs 33 for GG, 31.1 vs
22 for AG, and 8.5 vs 13 for AA.
Discussion
The ability to predict, in the pre-RCT setting, which
human EACs are radiochemosensitive has enormous
clinical relevance. This is because RCT carries substan-
tial toxicity, and because preoperative chemotherapy
alone, without radiotherapy, is a valid curative alterna-
tive to RCT[28,29]. The likelihood that a patient’s tumor
is radiochemosensitive may be incorporated into a risk/
benefit model at the time of diagnosis which could be
used as a clinical decision-making tool to select patients
for preoperative RCT vs chemotherapy alone. pCR is a
clinically relevant marker of radiochemosensitivity, due
to its consistent and strong association with overall sur-
vival in this disease[4]. Because traditional clinical-
pathologic factors in the pretreatment setting do not
adequately predict radiochemosensitivity, it is reasonable
to evaluate molecular or genetic factors[4,19].
In this study we found that 52% of EAC subjects had
the variant 399Gln allele in XRCC1, and that subjects
with the variant allele had five times higher odds of fail-
ing to achieve pCR after cisplatin-based RCT, compared
to subjects without the variant allele. To our knowledge,
our study is the first to assess this SNP in relation to
radiochemoresistance in a clinical trial cohort of EAC.
This association did not reach statistical significance at
the 0.05 alpha level, which may reflect our relatively
modest sample size. A number of observations support
the probability that our observed findings are real, and
would have reached greater statistical significance had
more samples been available for analysis. One, the only
60 (74% of 81) Patients with DNA who 
consented to correlative lab studies ± 
included in current study 
97 Patients enrolled for E1201 
16 Patients excluded 
 12 Ineligible 
 4   Untreated 
  
81 Patients from E1201 eligible for 
analysis 
Figure 1 Patient eligibility in E1201 and sample availability.
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other study we are aware of which assessed the relation-
ship between this SNP in a cohort of mostly EAC
patients receiving platin-based RCT and pCR (co-inves-
tigator X.W.) found the same association. Our cohort
was completely independent from the first and was ana-
lyzed using a different genotyping platform.
Two, our study employed strong methodology. Thera-
peutic approach, staging, and disease characteristics
were highly uniform, well-characterized, and prospec-
tively collected. Our subjects were accrued over a
recent, short time period across multiple centers, and
staged by modern methods. Only adenocarcinoma his-
tology was included. We focused on adenocarcinoma
because of its greater relevance in the U.S., and the epi-
demiologic and potential biologic differences compared
to squamous cell carcinoma[19]. Lab investigators
remained blinded to clinical outcomes.
Three, we found that tumor genotype reflected germ-
line genotype at the XRCC1 399 loci (19q13.2) in 90%
of informative cases, suggesting germline DNA may be
an appropriate surrogate of tumor genotype. To our
knowledge, this is the first reported assessment of AI
specifically in XRCC1 in EAC. Comparative genomic
hybridization (CGH) studies of EAC have not found
substantial genetic alterations in this general region
[30,31]. One study found >10% of 28 GEJ cancers
(including 3 cell lines and 2 xenografts) had gene ampli-
fication at a neighboring site (19q13.1) [31]; however,
the density of CGH coverage is not clearly reported [32]
so it is unknown whether amplification occurred at
XRCC1. Together, these AI data, which require further
evaluation and confirmation, provides biologic plausibil-
ity that assessing germline DNA is appropriate when
attempting to predict response to RCT in EAC tumors.
In addition, XRCC1 is a key player in BER, the major
repair pathway for nonbulky damaged bases, abasic sites,
and DNA single-stranded breaks after treatment with
Table 1 Genotype and therapeutic response
Baseline Frequency Association between SNPs and pCR
SNP Geno-type No. (%) Variant allele groupa vs major homozygote No pCR/pCR (No.) OR 95% CI p
XRCC1 Arg399Gln (rs25487) AA 12 (20)
AG 19 (32) AA or AG 29/2
GG 29 (48) GG 21/8 5.37 0.94-57.0 0.062
XRCC2 5’ flank (rs6464268) GG 1 (2)
GA 16 (27) GG or GA 13/4
AA 43 (72) AA 37/6 0.53 0.11-2.99 0.59
ERCC1 3’ flank (rs3212986) TT 0
GT 22 (37) GT 17/5
GG 38 (63) GG 33/5 0.52 0.10-2.60 0.54
XPD Lys751Gln (rs13181) GG 8 (13)
GT 29 (48) GG or GT 30/7
TT 23 (38) TT 20/3 0.64 0.10-3.3 0.83
XPD Asp312Asn (rs1799793) AA 7 (12)
AG 28 (47) AA or AG 28/7
GG 25 (42) GG 22/3 0.55 0.082-2.77 0.65
CI, confidence interval; OR, odds ratio for non-pCR of variant allele group as compared to the major homozygote; pCR, complete pathologic response; SNP, single
nucleotide polymorphism.
a The variant allele group consists of the variant allele homozygote and heterozygote in combination.
Table 2 Genotype and survival
Progression-free
survival
Overall Survival
SNP and
Genotype
Median
(months)
HR p Median
(months)
HR p
XRCC1:rs25487
AA or AG 31.5 1.4 0.41 23.7 0.86 0.66
GG NR (>38) 49.3
XRCC2:
rs6464628
GG or GA 22.9 1.6 0.24 53.5 1.3 0.52
AA NR (>31.5) 46.7
ERCC1:
rs3212986
GT or TT 37.9 1.1 0.78 46.7 0.96 0.90
GG NR (>31.5) 35.0
XPD:rs13181
GG or GT 46.5 0.63 0.25 46.7 0.67 0.27
TT 16.0 21.0
XPD:rs1799793
AA or AG NR (>40) 0.80 0.57 NR (>40) 0.59 0.14
GG 31.4 21.0
HR, hazard ratio; NR, not reached; SNP, single nucleotide polymorphism.
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ionizing radiation[33,34]. Prior reports in human popu-
lations suggested the 399Gln variant of XRCC1 was
associated with greater DNA and chromosomal damage
[16,35]. Worsened pCR and survival[18] related to the
variant may be due to increased genetic instability and
the development of multiple clonal populations, given
the substantial data linking chromosomal aberrations
and poor prognosis[15,18]. One co-investigator (G.L.)
assessed this XRCC1 SNP in patients with esophageal
cancer treated with cisplatin-based trimodality therapy
and, similar to the current study, did not find an asso-
ciation with disease-free or overall survival[36]. Also
consistent with our findings, the 399Gln variant allele
was associated with decreased tumor response (and
worse survival) in patients with stage III-IV non-small
cell lung cancer (NSCLC) and metastatic colorectal can-
cer, respectively, treated with platinum chemotherapy
[22,37]. By contrast, the variant allele was associated
with favorable OS in patients with stage IV squamous
cell carcinoma of the head and neck (SCCHN) treated
with cisplatin-based chemotherapy or RCT[12]. Investi-
gators of the latter study hypothesized their divergent
result may have been due to biologic or tissue-specific
factors underlying the greater chemosensitivity of
SCCHN, compared to lung cancer, or to the differing
types of platin compounds used in other studies (mostly
carboplatin in NSCLC and oxaliplatin in colorectal
cancer).
The XRCC1 SNP deviated somewhat from Hardy-
Weinberg equilibrium, with under-representation of the
heterozygote genotype vs over-representation of one of
the homozygous genotypes. This raises the possibility
that one of the homozygous genotypes increases EAC
risk, as supported by some [38] but not other [39,40]
case-control data; however, our study design does not
enable firm conclusions to be drawn.
Because this study focused on previously reported
alleles in a few genes, we have not accounted for the
potential influence of other SNPs on clinical outcome.
In addition, because the two arms of the study were
pooled, the study does not account for the potential dif-
ferential effects of the second chemoagent of each arm.
While the effect size noted in our study between the
XRCC1 SNP and pCR was considerable, the results did
not reach statistical significance at the alpha 0.05 level;
therefore, our results should be viewed with caution
pending validation in an independent cohort. Despite
substantial effort to identify prognostic or predictive
biomarkers in EAC, the process remains in its early
stages. Because chemo- or radiotherapy deliver their
effects through multigenic steps, it is unlikely that a sin-
gle SNP or marker will robustly predict therapeutic effi-
cacy. In the practical clinical context, a combination of
markers will likely be required. Our finding supports the
further evaluation of this XRCC1 SNP in larger cohorts.
Conclusion
EAC subjects with the variant 399Gln allele in XRCC1
had higher odds of radiochemoresistance compared to
subjects without the variant allele (p = 0.062). To our
knowledge, our study is the first to assess this SNP in
relation to radiochemoresistance in a clinical trial cohort
of EAC. These data support further investigation of this
SNP in larger EAC populations. In addition, our data
indicate that germline genotype may serve as a surrogate
for tumor genotype at this locus.
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